IRON 8-K SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

IRON ▲ +0.61% at T+20d

NEUTRAL call ✓ call won +0.61% · α vs SPY -4.35% · entry $67.59 → $68.00

Next anchor: T+60d in 7w

Last close $65.80 (close Jun 8) · -2.65% from $67.59 entry

Entry anchored
May 5, 05:15 AM ET
via Databento tick

T+1d

+1.57%

call +1.57% · α +0.18%

$68.65

settled 5w ago

T+5d

+2.43%

call +2.43% · α +0.44%

$69.23

settled 29d ago

T+20d

+0.61%

call +0.61% · α -4.35%

$68.00

settled 7d ago

T+60d

—

call — · α —

—

in 7w

Price Chart

Loading chart...

Executive Summary

Disc Medicine reported Q1 2026 results with a net loss of $63.5M ($1.65/share), wider than the $34.1M loss in Q1 2025, driven by increased R&D and SG&A spending. The company completed enrollment in the Phase 3 APOLLO study for bitopertin (topline data expected Q4 2026) and maintains a strong cash position of $730M, funding operations into 2029. The wider loss and lack of revenue are consistent with a clinical-stage biotech, but the stock will move on pipeline catalysts, not the financials.

Actionable Insight

The stock will trade on pipeline milestones, not quarterly financials. Key catalysts: bitopertin APOLLO topline data (Q4 2026), DISC-0974 ASCO presentation (June 2026), and DISC-3405 data (Q4 2026). Monitor for FDA Type A meeting outcome in Q2 2026.

Key Facts

Net loss of $63.5M for Q1 2026 vs $34.1M in Q1 2025
Net loss per share of $1.65 vs $1.02 in Q1 2025
Cash, cash equivalents, and marketable securities of $730.2M as of March 31, 2026
Completed enrollment of Phase 3 APOLLO study for bitopertin in EPP; topline data expected Q4 2026
Type A meeting with FDA scheduled for Q2 2026 to review bitopertin resubmission approach
Updated Phase 2 data for DISC-0974 in MF anemia selected for oral presentation at ASCO in June 2026
Phase 2 study of DISC-3405 in PV and Phase 1b study in SCD progressing; data expected Q4 2026

Financial Impact

Net loss widened by $29.4M YoY to $63.5M; cash burn of ~$61M in Q1 2026

net_losscash_positionr_and_d_expensessga_expenses

Risk Factors

Bitopertin received a Complete Response Letter (CRL) from FDA in Feb 2026; approval path uncertain
Widening net loss and increasing cash burn rate
Clinical-stage biotech with no approved products or revenue
Dilution risk from potential future equity offerings

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

95% bullish (19 analysts)

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001193125-26-205187
Document: iron-20260505.htm	0001193125-26-205187
Document: 0001193125-26-205187-index-headers.html	0001193125-26-205187
Document: 0001193125-26-205187-index.html	0001193125-26-205187
Document: 0001193125-26-205187.txt	0001193125-26-205187
8-K Data (Synthetic)	0001193125-26-205187

6 reports for IRON

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for IRON — sortable, filterable
	Type				Now
Jun 9, 2026 today	Press Release BULLISH ★ 6/10	$67.50 awaiting T+5	awaiting T+5	—	$65.80 (−2.52%)
Jun 1, 2026 8d ago	Press Release NEUTRAL ★ 4/10	$71.97 $67.00	▼ −6.91%	▼ −4.16%	$65.80 (−8.57%)
May 5, 2026 5w ago	8-K NEUTRAL ★ 4/10	$67.59 $69.23	▲ +2.43%	▲ +0.44%	$65.80 (−2.65%)
May 5, 2026 5w ago	Press Release NEUTRAL ★ 5/10	$67.59 $69.23	▲ +2.43%	▲ +0.44%	$65.80 (−2.65%)
Apr 13, 2026 8w ago	Insider Cluster BEARISH ★ 7/10	$68.46 $71.41	▼ −4.31%	▼ −1.01%	$65.80 (+3.89%)
Feb 26, 2026 14w ago	8-K BEARISH ★ 7/10	$67.91 $60.34	▲ +11.15%	▲ +10.02%	$65.80 (+3.11%)

US Market Status

Market Closed — Opens in 6h 53m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access